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AbstrAct
Objectives To explore the prevalence of Helicobacter 
pylori infection in Japan and the trends of its eradication 
therapy before and after the changes of the insurance 
coverage policy, first started in 2000, and expanded to 
cover H. pylori-positive gastritis in 2013. The impacts that 
the changes brought were estimated.
Methods In this retrospective observational study and 
simulation study based on health insurance claims data, 
product sales data and relevant studies, individuals 
who received triple therapy (amoxicillin, clarithromycin, 
proton-pump inhibitors or potassium-competitive acid 
blockers) were defined as the first-time patients for H. 
pylori eradication in two Japanese health insurance claims 
databases (from approximately 1.6 million and 10.5 million 
individuals). Each sales data of eradication packages and 
examination kits were used to estimate the number of H. 
pylori-eradicated individuals nationwide. The prevalence of 
H. pylori infection, including the future rate, was predicted 
using previous studies and the estimated population trend 
by a national institute. Cases completed prior to the policy 
change on insurance coverage were simulated to estimate 
what would have happened had there been no change in 
the policy.
results The numbers of patients first received eradication 
therapy were 81 119 and 170 993 from two databases. 
The nationwide estimated number of patients successfully 
eradicated was approximately 650 000 per year between 
2001 and 2012, whereas it rapidly rose to 1 380-000 per 
year in 2013. The estimated prevalence of infection in 
2050 is 5%, this rate was estimated to be 28% and 22% 
if the policy changes had not occurred in 2000 and 2013, 
respectively.
conclusions The impact of policy changes for H. pylori 
eradication therapy on the prevalence of infection was 
shown. The results suggest that insurance coverage 
expansion may also reduce the prevalence in other 
countries with a high prevalence of H. pylori infection if the 
reinfection is low.
IntrOductIOn
Throughout the world, gastric cancer is one 
of the most common cancers; 952 000 new 
patients were diagnosed in 2012.1 The inci-
dence of gastric cancer is higher in Asian 
countries; Korea, Japan and China have the 
first, third and fifth highest rates, respectively, 
in the world.2 In Japan, the prevalence and 
mortality of gastric cancer are constantly 
among the top three of all cancers. There-
fore, it is considered to be one of the highest 
priorities in preventive policy. Helicobacter 
pylori can cause gastric inflammation, which 
can then lead to gastric and duodenal ulcers, 
as well as gastric cancer.3–5 Thus, eradica-
tion of H. pylori is considered as an effective 
therapy in reducing the risk of those diseases.
Due to the concern of high gastric cancer 
prevalence in East Asian countries, some 
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Research
strengths and limitations of this study
 ► Demonstrates for the first time the impact of 
insurance policy expansion for Helicobacter  pylori 
eradication therapy in a quantitative manner based 
on an analysis of nationwide real-world data.
 ► Robust and reliable results were obtained from 
combinations of large-scale  insurance claims 
databases and sales data of the most commonly 
used eradication treatments and test kits.
 ► The success rate of eradication was obtained 
from previous studies; therefore, the rate might be 
different from current clinical practice.
 ► The health insurance claims databases have 
potential biases: in one database,the information on 
individuals older than 65 years is limited because 
it is the information from employed individuals and 
their family members, whereas another database 
included the data only from large hospitals.
 o
n




pen: first published as 10.1136/bmjopen-2017-015855 on 31 July 2017. Downloaded from 
2 Hiroi S, et al. BMJ Open 2017;7:e015855. doi:10.1136/bmjopen-2017-015855
Open Access 
preventive programmes have been launched to reduce 
the incidence of gastric cancer. In Korea, a cancer 
screening programme was established by the government 
to provide for almost all people of eligible age (40 years or 
older for gastric cancer) with free screening or provision 
at minimum cost in 1999.6 Large clinical trials and health 
economic studies have been conducted in China, and a 
consensus statement was formulated to encourage H. pylori 
eradication therapy.6 7 In Taiwan, the results of a commu-
nity-level large screening and eradication programme, as 
well as a health economic evaluation, support the efficacy 
of H. pylori eradication therapy.8 In Japan, in November 
2000, based on the results of diverse clinical studies,3 9–20 
the government approved the addition of H. pylori erad-
ication therapy in their insurance policy as a treatment 
for H. pylori-positive gastric ulcer and duodenal ulcer. 
Furthermore, insurance coverage was expanded in June 
2010 to include gastric mucosa-associated lymphoid tissue 
lymphoma, idiopathic thrombocytopenic purpura and 
postendoscopic resection of early gastric cancer, and in 
February 2013, to include H. pylori-positive gastritis based 
on the recommendations of Japanese guideline.21
Japanese health insurance is a system of universal 
coverage; the effect of change in health insurance 
coverage policy is spread throughout the nation. In terms 
of H. pylori eradication, anyone diagnosed with a disease 
covered for eradication therapy by health insurance can 
receive eradication therapy with coverage. Therefore, 
health insurance reimbursement seems to have the same 
or greater impact on clinical practice as recommenda-
tions from diagnostic/treatment guidelines in countries 
where universal health insurance coverage is established, 
such as in Japan and Korea. Various sizes of preventative 
programmes for gastric cancer have been implemented 
in the high prevalence countries for both gastric cancer 
and H. pylori infection. In some countries, H. pylori erad-
ication therapy for patients with H. pylori-positive gastric 
ulcer and duodenal ulcer has been covered by national 
health insurance. However, eradication therapy for H. 
pylori-positive gastritis has not been covered to date in 
these countries other than Japan.8 The effect of insur-
ance coverage expansion on the prevalence of H. pylori 
infection has been evaluated in only a few studies at the 
community level in Japan.22 23 Nonetheless, the nation-
al-level prevalence rate of H. pylori infection has not 
been reported and its change has not been assessed after 
the insurance coverage for H. pylori eradication therapy 
was expanded to include H. pylori-positive gastritis in 
2013. The progressive insurance expansion was reported 
to be efficient,24 and the incidence of peptic ulcer has 
decreased since the change in insurance coverage policy 
for H. pylori eradication in 2000.25 They also estimated 
that gastric cancer mortality would decrease based on 
the assumption that 50% of patients infected with H. 
pylori would receive eradication therapy.26 However, this 
estimate was based on neither the observed number of 
patients undergoing H. pylori eradication nor the preva-
lence rate of infection. To evaluate the impact of changes 
to the insurance policy on the incidence of various 
diseases, including gastric cancer, it is necessary to eluci-
date the national trend of eradication therapy and the 
prevalence rate of infection before and after the changes 
in the insurance policy.
The primary objective of this study was to assess how 
health insurance policy changes have impacted eradica-
tion therapy and the prevalence rate of H. pylori infection 
in Japan. Furthermore, the future effect, as a result of the 
policy changes, on the prevalence of H. pylori infection 
was evaluated. In this study, health insurance claims data-
bases and product sales data were used to estimate the 
number of eradication treatments. The successful eradi-
cation rate from 2000 onwards, at which time the health 
insurance began its coverage for the eradication therapy, 
was also estimated. The prevalence rate of infection 
and the number of infected individuals up to 2060 were 
predicted as based on the above data analysis and the prev-
alence rate of H. pylori infection as reported in previous 
studies. Furthermore, a simulation was conducted to esti-
mate what the probable effects would be had the policy 
changes not been made.
MethOds
Data sources
Insurance claims databases from Japan Medical Data 
Center (JMDC) from January 2005 to December 2015 
and Medical Data Vision (MDV) from April 2008 to 
December 2015 were used for the analyses. The JMDC 
database is a registry of health insurance claims and 
medical examination records for insured individuals 
and their families in more than 50 health insurance soci-
eties. Because this database only included information on 
company employees and their families, the information 
for those older than 65 years was limited. Also, there were 
no data for those older than 75 years. Until 2014, this 
database covered 1.6 million individuals which accounted 
for 1% of the Japanese population. The medical database 
from MDV covered 10.5 million individuals in 192 acute 
care hospitals using diagnostic procedure combination/
per diem payment system (DPC/PDPS). It included 11% 
of acute care hospitals in Japan with the number of beds 
from 20 to more than 1000. These databases included the 
patient’s gender, age, diagnosis, prescription information 
and so on. Diagnosis information is based on the Interna-
tional Classification of Diseases, tenth revision, and drugs 
are coded in the Anatomical Therapeutic Chemical Clas-
sification System. Both databases included anonymous 
and personally unidentifiable data.
To estimate the nationwide number of infected individ-
uals, product sales data for the most common eradication 
medicine and test kit for H. pylori infection were analysed. 
The sales data for eradication medicine, Lansap (Takeda 
Pharmaceutical), which consists of lansoprazole, amoxi-
cillin and clarithromycin in one package, was provided 
by the manufacturer from December 2002 to December 
2015. The data for 13C-urea breath test (UBIT, Otsuka 
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Table 1 Studies on the number of Helicobacter pylori-infected individuals and prevalence rate of infection
First author No of subjects Population Study design
Observation 
year
Asaka27 426 Asymptomatic children, students and adults 
(participating at the health screening centre) 
living in Sapporo, Hokkaido
Observational study 1990
Fujisawa31 349 Healthy persons living in seven prefectures in 




Watabe32 6 983 Participants in a mass health appraisal 
programme
Observational study 1996
Ueda33 14 716 Individuals who underwent a health check-
up in seven prefectures (Hokkaido, Aomori, 
Yamagata, Gunma, Aichi, Shiga and Kagawa)
Observational study 2005
Shiota34 5 550 Patients of Oita University Hospital, Oita, Japan Observational study 2009
Pharmaceutical) from November 2000 to December 
2015 were as well obtained.
To determine the trend in the number of H. pylori-in-
fected individuals, previously published Japanese studies 
were used (table 1).
study design
This study is a retrospective observational study and simu-
lation study based on the health insurance claims data, 
product sales data and relevant published studies. The 
steps were as follows: first, the number of individuals 
who received the eradication therapy and those who had 
successful eradication were estimated based on the anal-
yses of the health insurance claims databases and product 
sales data; second, the trend in the number of H. pylo-
ri-infected individuals was determined from previously 
published studies; third, the prevalence rate and trend 
of H. pylori infection were estimated and forecasted from 
the results of the first and second step. Finally, to fully 
evaluate the impact of the policy changes, a simulation 
was made considering effects which likely would have 
occurred without the insurance policy changes in 2000 
and 2013.
Patient identification and analysis
In the JMDC and MDV databases, the individuals who 
received triple therapy, either the primary eradication 
package (such as Lansap and other packaged products) 
or the combination of amoxicillin, clarithromycin and 
either proton-pump inhibitors or potassium-competi-
tive acid blockers (P-CABs) (all prescribed within the 
same month), were defined as individuals with primary 
eradication of H. pylori. The drugs used for the therapy 
were defined by product name in JMDC database and 
remuneration code in MDV database. The examination 
was defined by remuneration code, and the diagnosis 
for those who had eradicated was defined by name of 
diagnosis in both databases. To estimate the number of 
individuals who received primary eradication therapy in 
the nation, the following were calculated in these data-
bases:
1. Percentage of individuals who used Lansap for 
primary eradication therapy to all individuals who 
received the primary eradication.
2. Percentage of individuals who received UBIT for the 
H. pylori test after eradication to all individuals who 
took the H. pylori test.
To calculate the number of individuals who achieved 
successful eradication, the following were assumed 
(figure 1): 
 ► The primary and secondary success rates of 
eradication for this study were presumed to be 75% 
and 90%, respectively, based on previous studies 
in Japan.25 27 Secondary eradication was premised 
to be performed for all those who failed primary 
eradication. Therefore, the success rate of the 
eradications was estimated to be 98% of the primary 
eradication, and the percentage was used as the 
success rate in this study.
 ► New infection in adulthood was reported to be rare28 
and reinfection per year after the eradication therapy 
in Japan is reported to be approximately 1%29 30; 
however, it was assumed to be 0% in this study.
The nationwide number of individuals who received 
primary eradication was estimated based on the above 
points 1. and 2. with sales data of Lansap and UBIT as 
follows:
 ► The monthly number of individuals who received 
primary eradication from January 2010 was calculated 
as the mean of four estimates (Lansap-base from MDV 
and JMDV, and UBIT-base from MDV and JMDC).
 ► The monthly number of individuals who received 
primary eradication from January 2006 to December 
2009 was calculated as the mean of two estimates from 
the JMDC database (Lansap-base and UBIT-base).
 ► The monthly number of individuals who received 
primary eradication from November 2000 to 
December 2005 was extrapolated using the sales 
number of UBIT in each month and the UBIT share 
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Figure 1 The model used to calculate the number of individuals with successful Helicobacter pylori eradication.
rate in 2006 on the assumption that the share rate in 
this period was the same as that in 2006.
The formulae used are as follows:
 ► (Successful eradication number)YM = (Primary 
successful eradication number)YM + (Secondary 
successful eradication number)YM
 ► (Primary successful eradication number)YM = (Primary 
eradication number)YM × (Primary eradication success 
rate, 75%)
 ► (Secondary successful eradication number)YM= 
((Primary eradication number)YM − (Primary 
successful eradication number)YM) × (Secondary 
eradication success rate, 90%)
 ► (Primary eradication number)YM = ((Primary 
eradication number with Lansap)YM,JMDC + (Primary 
eradication number with Lansap)YM,MDV + (Primary 
eradication number with UBIT)YM,JMDC + (Primary 
eradication number with UBIT)YM,MDV)/4
 ► (Primary eradication number with Lansap)YM,database = 
(Sales number of Lansap)YM / (Share of Lansap)YM,database
 ► (Primary eradication number with UBIT)YM,database = 
(Examination number)YM,database × (Ratio of primary 
eradication to total examination)YM,database
 ► (Examination number)YM,database = (Sales number of 
UBIT)YM / (Share of UBIT)YM,database where YM is year 
month and database = JMDC or MDV database.
The number of infected individuals and prevalence rate 
of infection were estimated based on the previous Japa-
nese studies shown in table 1. The number of infected 
individuals until March 2013 was estimated from previous 
studies27 31–34 and vital statistics in Japan conducted by 
Ministry of Health, Labour and Welfare.35 An exponen-
tial decay approximation curve was calculated based on 
the results of the previous studies until 2000. After 2000, 
the estimated mean monthly number of individuals 
who achieved successful eradication from January 2001 
to March 2013 was taken into account. The number of 
infected individuals from April 2013 was estimated using 
the estimated mean monthly number of individuals 
who achieved successful eradication from April 2013 to 
December 2015, giving consideration to the decrease in 






DOBYRNational PopulationDOBYR, CY×Prevalence RateDOBYR, CY∑
DOBYRNational PopulationDOBYR, CY
 
where (Prevalence rate)DOBYR,CY is the prevalence rate of 
H. pylori infection by birth year in each observation year 
calculated in this study, and (National population)DOBYR,CY 
is the population by birth year in each observation year, 
where DOBYR is birth year by 5 years and CY is the 
calendar year of observation of each study. An expo-
nential parameter that minimises the sum of squared 
distances from (Infection number)CY was calculated (least 
squares method), assuming the decrease of the number 
of H. pylori infected individuals by any reason other than 
eradication (ie, ageing) followed an exponential function 
and the decrease of that by eradication was constant from 
2001 to 2013.
Assuming that H. pylori infection would be decreasing 
exponentially after 2015 (by consideration of the natural 
decrease due to the death of older infected individuals), 
a simulation was performed using the number of infected 
individuals obtained in the previous section and the popu-
lation forecast from the National Institute of Population 
and Social Security Research36 to predict the number of 
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infected individuals in the future. The prevalence rate 
of infection was also simulated for the case of no policy 
change regarding insurance coverage in 2000 and 2013. 
This was simulated as follows:
1. The number of H. pylori-infected individuals calculated 
in the previous section was taken to be (Infection 
number)CY before 2013.
2. The number of H. pylori-infected individuals from 
2013 to 2015 was assumed to be decreased from 
(Infection number)CY before 2013, based on the 
estimated number of individuals who achieved 
successful eradication by the analysis of the JMDC and 
MDV databases and sales data of drugs.
3. If case 0, (Prevalence rate)CY,case = (Infection number)CY 
/ (National population)CY, in 1975≤CY≤2015 or 
(Prevalence rate)CY,case / (Prevalence rate)CY-1,case = 
(Prevalence rate)CY−1,case / (Prevalence rate)CY−2,case, in 
2016≤CY.
4. If case 1, (Prevalence rate)CY,case = (Infection number)CY 
/ (National population)CY, in 1975≤CY≤2000 or 
(Prevalence rate)CY,case / (Prevalence rate)CY-1,case = 
(Prevalence rate)CY−1,case / (Prevalence rate)CY−2,case, in 
2001≤CY.
5. If case 2, (Prevalence rate)CY,case = (Infection number)CY 
/ (National population)CY, in 1975≤CY≤2012 or 
(Prevalence rate)CY,case / (Prevalence rate)CY−1,case = 
(Prevalence rate)CY−1,case / (Prevalence rate)CY−2,case, in 
2013≤CY.
Case 0 is with the current policy; case 1 or case 2 represents 
the case in which policy change had not occurred in 2000 
or 2013.
Statistical analysis was carried out using Excel 2010 
(Microsoft) and SAS V.9.4 (SAS Institute).
results
Patient characteristics
The total number of individuals who received primary 
eradication was 81 119 (mean age 36.8 years, males 61%) 
from the JMDC database and 1 70 993 (mean age 60.6 
years, males 57%) from the MDV database. The charac-
teristics for each year are shown in online supplementary 
appendix, table S1.).
trend in the number of individuals with the primary 
eradication therapy and successful eradication
The difference among the four (Lansap-base from MDV 
and JMDV, and UBIT-base from MDV and JMDC) esti-
mated numbers of individuals who received primary 
eradication was confirmed to be minimal after 2010 (see 
online supplementary appendix,  figure S1). The nation-
wide number of individuals who had successful eradication 
(both first line and second line) was estimated as shown 
in figure 2. The number was approximately 650 000 per 
year between 2001 and 2012, which has reached a steady 
state of approximately 700 000 per year after an increase 
in 2006. However, there was a slight decrease in 2011. It 
markedly increased to 1 380 000 in 2013, which is more 
than double the number observed in 2012. In the diag-
noses for those who had successful eradication treatment 
(figure 2), gastritis accounted for more than half of the 
diagnoses since 2013. The average number of individ-
uals who received successful eradication treatment up to 
March 2013 was 54 000 per month, whereas it was 124 000 
per month after March 2013. The cumulative total of 
individuals who received successful eradication treatment 
was more than 10 million up to September 2014.
trend in the number of infected individuals and the prevalence 
rate of infection
Figure 3A illustrates the prevalence rate of H. pylori infec-
tion by birth year from previous studies. This shows higher 
prevalence rates of infection in the cohorts with earlier 
birth years. Also, there was a tendency for the difference 
of prevalence rates of infection among studies to be 
larger in those with an earlier birth year, and the rate was 
lower in later observations. The overall estimated preva-
lence rate of infection was lower in later years (figure 3B). 
The lines were fitted after taking the effect of insurance 
policy change in November 2011 into account, shown in 
figure 3B.
trend and prediction of H. pylori infection and the effect of 
insurance policy changes
The pattern of the number of infected individuals from 
2016 in Japan was predicted (blue broken line in figure 4) 
based on the trend in the number of infected individuals 
derived from the results above and the population fore-
cast.35 The patterns, in the case without policy changes in 
insurance coverage in 2000 and 2013, were also simulated 
(red and green broken lines in figure 4). The simulation 
showed that the number of infected individuals would 
decrease to 16 200 000 individuals in 2030, or 14% of the 
population, and further decrease to 5% of the population 
in 2050. These figures would have been 28% and 21% in 
2030 if the policy changes had not occurred in 2000 and 
2013, respectively.
dIscussIOn
This study described the status of eradication therapy and 
trend of H. pylori infection using large insurance claims 
databases that reflected actual clinical practice at the 
national level in Japan. The analysis showed that the prev-
alence rate of H. pylori infection has decreased after the 
approval to include eradication therapy in the insurance 
policy in 2000. The number of successful eradications 
more than doubled immediately after insurance coverage 
for H. pylori eradication therapy was expanded in 2013. 
The simulation indicated that the prevalence rate of H. 
pylori infection would decrease and reach approximately 
14% in 2030 and 5.4% in 2050.
Although it is difficult to compare the prevalence rate 
of infection among studies due to time and sample differ-
ence, it is worthwhile to compare the rate with other 
countries. The prevalence rate of H. pylori infection varies 
markedly in different countries; in general, it is higher in 
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Figure 2 Annual number of individuals who had successful Helicobacter pylori eradication (both first line and second line). 
*Others: gastric mucosa associated lymphoid tissue lymphoma, idiopathic thrombocytopenic purpura and postendoscopic 
resection of early gastric cancer. 
developing countries and lower in developed countries.37 
The prevalence rate of infection was reported to be 92% 
in Bangladesh,38 75% in Vietnam,39 41%–72% in China40 
and 54%–60% in Korea,41 42 whereas it was 15%–22% in 
Australia43 44 and 8%–27% in the USA.45 46 Although the 
estimate of the prevalence rate of H. pylori infection in 
our study was 43% in Japan in 2000, based on our simu-
lation, the prevalence rate of infection in Japan in 2030 
with expanded insurance coverage would be almost the 
same as the Australian rate (15%) and it would reach the 
North American level (8%–27%) by approximately 2050.
The estimate from the previous studies indicated a 
higher prevalence rate of infection in older cohorts, 
which can be explained by environmental factors like 
poor sanitation.47 48 It has also been suggested that nowa-
days H. pylori infection occurs in childhood in Japan.49 50 
As a result, the number of infections would have naturally 
decreased even without eradication therapy due to the 
death of older infected individuals. However, our simula-
tion showed that the prevalence rate of infection would 
have been higher than 14% and 7% in 2030 if the policy 
changes had not occurred in 2000 and 2013, respec-
tively. It was, therefore, evident that those insurance 
policy changes had contributed to the reduction in the 
prevalence of H. pylori infection. Japan has established a 
universal health insurance coverage system, which means 
that by law all Japanese residents are entitled to health 
insurance coverage for medical treatments. This system 
has a great impact on the dissemination of medical treat-
ments; consequently, the use of eradication therapy is 
highly influenced by the presence of the health insurance 
and coverage for diseases.
The results of this study could be a good indicator for 
the implementation of insurance coverage for eradica-
tion of H. pylori in countries where H. pylori is prevalent, 
especially the East Asian countries. Countries and regions, 
such as Korea, China and Taiwan, have been conducting 
clinical trials of H. pylori eradication; however, they have 
not yet established any policy for H. pylori eradication. 
This study is likely to be used as one of the references 
in considering effect on policy change in such countries. 
This study might also be important in providing direction 
for future research in Japan. In 2016, the revised edition 
of the Japanese Guideline for Diagnosis and Treatment 
for H. pylori Infection was published following that of 
2009. In the latest guideline, the expansion of insur-
ance coverage for the treatment for H. pylori gastritis in 
2013 is described.51 Also, a regimen with P-CAB-based 
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Figure 3 Trends in (A) the percentages of Helicobacter pylori infection by birth year based on previous studies and (B) the 
nationwide number of infected individuals as estimated based on the previous studies. *Data from the study by Watabe et al32 
were excluded in (A) as that study divided the age group into two age groups: below and above age 60 years.
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Figure 4 Trend and prediction of the number of Helicobacter pylori-infected individuals. *Case 0, in current policy; †case 1, if 
policy change had not occurred in 2000; ‡case 2, if policy change had not occurred in 2013.
triple therapy, which is newly described in the guideline, 
demonstrated a high eradication rate compared with 
the conventional proton-pump inhibitor-based triple 
therapy.51 52 It seems that the prevalence rate of infection 
could be further reduced in Japan.
comparison with other studies
There have been some community-level studies inves-
tigating the status of eradication in clinical practices in 
Japan.22 23 Nevertheless, to our knowledge, there was no 
study describing the status of eradication therapy at the 
national level. Asaka et al have reported that the insurance 
policy change could increase the number of eradications, 
reduce the number of infected individuals and decrease 
mortality from gastric cancer.24 25 They estimated that 
the number of deaths from gastric cancer would reach 
60 000 in 2020 without any countermeasures, whereas 
it would be half if 50% of infected individuals receive 
eradication therapy. However, this assumption was not 
based on actual observations. Our study, using real-world 
data reflecting actual medical practice, showed a rapid 
increase in patients receiving H. pylori eradication, after 
the insurance policy change in 2013.
strengths and limitations of this study
Here, a national-level evaluation using real-world data, 
allowed us to analyse the impact of insurance policy 
expansion for H. pylori eradication therapy in a quan-
titative manner. Furthermore, robust and reliable 
results were obtained from combinations of large-scale 
insurance claims databases and sales data of the most 
commonly used eradication treatments and test kits.
However, this study has several limitations. First, the 
success rate of eradication was obtained from previous 
studies25 27; thus, the rate might be different from clin-
ical practice, including the possibility that it may be 
estimated higher than the actual rate considering the 
effect of the increase in bacteria resistant to antibiotics. 
Nevertheless, the success rate in this study is believed to 
be close to the actual rate. Second, the health insurance 
claims databases have potential biases. The information 
available was limited for those older than 65 years in 
the JMDC database because it consisted of information 
on employed individuals and their family members. In 
addition, those who were self-employed and employees 
in small-to-medium sized enterprises were not included. 
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The information in the MDV database was obtained from 
the hospital using DPC/PDPS. Indeed, the mean ages 
of individuals who received primary eradication in both 
databases were different. However, the product share 
rates calculated in both databases were very similar after 
2010, and the estimates of the number of individuals 
with the primary eradication were almost identical in 
both databases. Therefore, the impact of the different 
age distribution was believed to be minimal, and the 
estimates are believed to be accurate.
Despite these limitations, this study used the informa-
tion from reliable clinical studies and large databases 
covering a significant number of Japanese citizens. 
Consequently, it is believed that the information 
presented here reflects the clinical status in Japan.
conclusion and policy implications
This study described and forecasted the trend of H. pylori 
eradication therapy and assessed the impact of insur-
ance policy change on the prevalence rate of H. pylori 
infection. It has demonstrated that the policy change 
was associated with a reduction in the prevalence rate of 
H. pylori infection in Japan. Furthermore, it is expected 
to lead to a reduction in the incidence of gastric cancer. 
Adaptation of a similar nationwide health insurance 
coverage plan for H. pylori eradication by other high 
risk countries and regions may reduce the prevalence of 
H. pylori infection in the short and medium terms and 
may also have the possibility to have a positive effect on 
the incidence of H. pylori-related conditions, including 
gastric cancer, in the future.
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